Prof. Dr. ÖZGE GÜMÜŞAY

Yayın Ağı

Makaleler 84

1. Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer

Çetin B., Erdem D., Karaman I., GÜMÜŞAY Ö.

Current Treatment Options in Oncology , cilt.27, sa.1, 2026 (SCI-Expanded, Scopus)

2. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

Güren A. K., DEMİRCAN N. C., GÜMÜŞAY Ö., Şimşek E. T., Kemik F., KARAOĞLU Ç., et al.

Immunotherapy , cilt.18, sa.4, ss.317-326, 2026 (SCI-Expanded, Scopus)

3. Causes of diagnostic and treatment delays in locally advanced breast cancer: a nationwide multicenter survey and electronic health records analysis in Turkiye

Karadeniz Cakmak G., Tali U., Balbaloglu H., Tasdoven I., Ozkurt E., KARANLIK H., et al.

EUROPEAN JOURNAL OF PUBLIC HEALTH , cilt.35, sa.6, 2025 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

4. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., Gumusay Ö., Guven D. C., Aksoy S., Basaran G., et al.

Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus)

5. The Etiologic Causes of Diagnostic Delay in Locally Advanced Breast Cancer: _x000B_A Multicentric Nationwide Trial

Cakmak G. K., Ozkurt E., KARANLIK H., Dogan L., Gunay S., Basim P., et al.

CLINICAL CANCER RESEARCH , cilt.31, sa.12, 2025 (SCI-Expanded, Scopus)

6. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Dülgar Ö., Türker S., BAŞARAN G., Araz M., Sümbül A. T., Çağlayan D., et al.

Journal of Chemotherapy , cilt.37, sa.4, ss.334-340, 2025 (SCI-Expanded, Scopus)

7. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.

BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

8. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

Yasar H. A., Aktas B. Y., Ucar G., Goksu S. S., Bilgetekin I., Cakar B., et al.

Clinical Genitourinary Cancer , cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)

9. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

Gümüşay Ö., Huppert L. A., Magbanua M. J. M., Wabl C. A., Assefa M., Chien A. J., et al.

BREAST CANCER RESEARCH AND TREATMENT , cilt.203, sa.2, ss.197-204, 2024 (SCI-Expanded, Scopus)

10. PET/CT, an important imaging modality in the management of sarcoma patients.

Kayacan E., Üner A., Gümüşay Ö., Akdemir Ü. Ö.

Medicine Science , cilt.12, sa.4, ss.1-4, 2023 (TRDizin)

11. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Bilici A., Koca S., Karaagac M., Aydin S. G., Eraslan E., Kaplan M. A., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.11, ss.8243-8253, 2023 (SCI-Expanded, Scopus)

12. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer

Huppert L. A., Gümüşay Ö., Idossa D., Rugo H. S.

CA-A CANCER JOURNAL FOR CLINICIANS , cilt.73, sa.5, ss.480-515, 2023 (SCI-Expanded, Scopus)

13. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers

Çetin B., Wabl C. A., Gümüşay Ö.

IMMUNOTHERAPY , cilt.15, sa.12, ss.945-962, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

Gümüşay Ö., Çetin B.

N Engl J Med , cilt.31, sa.389(9), ss.866-867, 2023 (Hakemli Dergi)

15. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

Kahraman S., Erul E., Seyyar M., Gumusay Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , 2023 (SCI-Expanded, Scopus)

16. Diagnostic Value of Target Sign and Apparent Diffusion Coefficient Measurements in the Differentiation between Hepatocelular Carcinoma and Liver Metastasis on Diffusion Weighted Magnetic Resonance Imaging

Albayrak E., Gümüşay Ö., Server S.

JOURNAL OF CONTEMPORARY MEDICINE , cilt.13, sa.3, ss.473-478, 2023 (Hakemli Dergi)

17. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study

Kahraman S., Gümüşay Ö., Başaran G., Çabuk D., Aydıner A., Paydaş S., et al.

ESMO OPEN , cilt.8, sa.1, ss.1-2, 2023 (SCI-Expanded, Scopus)

18. Alpelisib induced interstitial lung disease in a patient with advanced breast cancer

Isiklar A., Basaran G., Sepin B., Gumusay Ö., Kocagoz A. S., Cuhadaroglu Ç.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.29, sa.2, ss.484-488, 2023 (SCI-Expanded, Scopus)

19. Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?

Cetin B., Wabl C. A., GÜMÜŞAY Ö.

FUTURE ONCOLOGY , sa.39, ss.4235-4238, 2022 (SCI-Expanded, Scopus)

20. The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases

Gumusay Ö., Huppert L. A., Behr S. C., Rugo H. S.

BREAST , cilt.63, ss.149-156, 2022 (SCI-Expanded, Scopus)

21. Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.

Isıklar A., Soyder A., Gümüşay Ö., Basaran G.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16_suppl, ss.1-5, 2022 (SCI-Expanded, Scopus)

22. Emerging treatment strategies for metastatic triple-negative breast cancer

Huppert L. A., Gumusay Ö., Rugo H. S.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , cilt.14, 2022 (SCI-Expanded, Scopus)

23. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management Optimal Management for Renal Cell Cancer Patients

Cetin B., Wabl C. A., Gumusay Ö.

CURRENT TREATMENT OPTIONS IN ONCOLOGY , cilt.23, sa.4, ss.609-629, 2022 (SCI-Expanded, Scopus)

24. Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Magbanua M. J. M., Gumusay Ö., Kurzrock R., van't Veer L. J., Rugo H. S.

FRONTIERS IN ONCOLOGY , cilt.12, 2022 (SCI-Expanded, Scopus)

25. Optimal Treatment for Patients with Oligometastatic Prostate Cancer

Cetin B., Wabl C. A., Gumusay Ö.

UROLOGIA INTERNATIONALIS , cilt.106, sa.3, ss.217-226, 2022 (SCI-Expanded, Scopus)

26. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer

Cetin B., Wabl C. A., Gumusay Ö.

FUTURE ONCOLOGY , cilt.18, sa.9, ss.1143-1157, 2022 (SCI-Expanded, Scopus)

27. Immunotherapy toxicity: identification and management

Gumusay Ö., Callan J., Rugo H. S.

BREAST CANCER RESEARCH AND TREATMENT , cilt.192, sa.1, ss.1-17, 2022 (SCI-Expanded, Scopus)

28. Role of Interleukin-6 Gene Variants in the Development of Oral Squamous Cell Carcinoma

Gumusay Ö., Yigit S., Nursal A. F., Tekcan A., DAGMURA H., Kuruca N.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.37, sa.4, ss.371-378, 2022 (ESCI, Scopus)

29. Merkel cell carcinoma in Turkey: A multicentric study

Yildiz F., Demirci U., Kucukarda A., BÜYÜKŞİMŞEK M., Sakalar T., Topcu T. O., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , sa.6, ss.1525-1529, 2021 (SCI-Expanded, Scopus)

30. Trials of Immunotherapy in Triple Negative Breast Cancer

Gumusay Ö., Wabl C. A., Rugo H. S.

CURRENT BREAST CANCER REPORTS , cilt.13, sa.3, ss.171-185, 2021 (ESCI, Scopus)

31. Understanding relevant immune mechanisms in gastrointestinal oncology

Cetin B., Gumusay Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.5, ss.1222-1234, 2021 (SCI-Expanded, Scopus)

32. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib

Cetin B., Gonul I. I., Gumusay Ö., AFŞAR B., Bilgetekin I., ÖZET A., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.17, sa.2, ss.408-413, 2021 (SCI-Expanded, Scopus)

33. eNOS and VEGF Variants Might Increase the Risk of Pancreatic Cancer

DAGMURA H., Yigit S., Gumusay Ö., Nursal A. F., Daldal E., Karakus N.

CYTOLOGY AND GENETICS , cilt.55, sa.2, ss.177-182, 2021 (SCI-Expanded, Scopus)

34. Possible Association of PER2/PER3 Variable Number Tandem Repeat Polymorphism Variants with Susceptibility and Clinical Characteristics in Pancreatic Cancer

DAGMURA H., Yigit S., Nursal A. F., Duman E., Gumusay Ö.

GENETIC TESTING AND MOLECULAR BIOMARKERS , cilt.25, sa.2, ss.124-130, 2021 (SCI-Expanded, Scopus)

35. Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC)

Gumusay Ö., Magbanua M. J. M., Majure M. C., Deal T., Renslo J. R., Wabl C. A., et al.

CANCER RESEARCH , sa.4, 2021 (SCI-Expanded, Scopus)

36. The DNA damaging revolution

Cetin B., Wabl C. A., Gumusay Ö.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.156, 2020 (SCI-Expanded, Scopus)

37. Can you draw the picture of happiness- Treatment of a young woman with breast cancer during the COVID-19 pandemic

Cetin B., RAKICI S., Gumusay Ö.

ASIAN JOURNAL OF PSYCHIATRY , cilt.52, 2020 (SCI-Expanded, Scopus)

38. Pembrolizumab for Early Triple-Negative Breast Cancer

Cetin B., Gumusay Ö.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.382, sa.26, 2020 (SCI-Expanded, Scopus)

39. Genetic Variations of miRNAs and the Risk of Oral Squamous Cell Carcinoma: A Case-control Study

Yilmaz K., Gumusay Ö., Nursal A. F., Karakus N., Yigit S.

HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , cilt.58, sa.3, ss.268-273, 2020 (ESCI, Scopus, TRDizin)

40. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology.

Gumusay Ö., Vitiello P. P., Wabl C., Corcoran R. B., Bardelli A., Rugo H. S.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting , cilt.40, 2020 (Scopus)

41. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.

Yildiz B., Kucukarda A., Gokyer A., Gokcen Demiray A., Paydas S., Pinar Aral I., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.25, sa.2, ss.1130-1135, 2020 (SCI-Expanded, Scopus)

42. C Deletion in Exon 4 Codon 63 of p53 Gene in Turkish Patients with Oral Squamous Cell Carcinoma

Tekcan A., Gumusay Ö., Nursal A. F., Yigit S., Yildiz S., Tumer M. K.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.35, sa.2, ss.163-166, 2020 (ESCI, Scopus, TRDizin)

43. Contralateral Testicular Metastasis of Renal Cell Carcinoma: A Case Report

Kolukcu E., Kilic S., Parlaktas B. S., Deresoy F. A., Atilgan D., Gumusay Ö., et al.

EURASIAN JOURNAL OF MEDICINE , cilt.51, sa.3, ss.310-312, 2019 (ESCI, Scopus, TRDizin)

44. Failure of Concurrent Chemoradiotherapy for Organ Preservation in Laryngeal Cancer: Survival Outcomes and Recurrence Patterns

AYDİL U., AKMANSU M., Gumusay Ö., Eravci F. C., Bakkal F. K., Yazici O., et al.

ENT-EAR NOSE & THROAT JOURNAL , cilt.98, sa.7, 2019 (SCI-Expanded, Scopus)

45. Impact of the Functional VNTR Variants of the Interleukin-1 Receptor Antagonist and Interleukin-4 Genes on Oral Squamous Cell Carcinoma

Gumusay Ö., Nursal A. F., Yigit S., Tekcan A., Oz T.

ISTANBUL MEDICAL JOURNAL , cilt.20, sa.3, ss.202-207, 2019 (ESCI, TRDizin)

46. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., Bilici A., ÇİÇİN İ., KÖSTEK O., Kaplan M. A., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus)

47. Impact of the functional VNTR variants of the IL-1RA and IL-4 genes on oral squamous cell carcinoma

GÜMÜŞAY Ö., NURSAL A. F., YİĞİT S., TEKCAN A., Oz T.

Istanbul Medical Journal , cilt.0, sa.0, 2019 (TRDizin)

48. EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis

Ozturk A., Celik S., Kodaz H., Yildiz I., Ocak A., Hacibekiroglu I., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2018 (SCI-Expanded, Scopus)

49. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

Cetin B., Gonul I. I., Gumusay Ö., Bilgetekin I., Algin E., ÖZET A., et al.

NEUROPATHOLOGY , cilt.38, sa.5, ss.457-462, 2018 (SCI-Expanded, Scopus)

50. Merkel cell carcinoma in Turkey: A multicentric study.

Yildiz F., BÜYÜKŞİMŞEK M., Sakalar T., AYDIN ÜLGEN Ö., TURNA Z. H., Babacan N. A., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.15, 2018 (SCI-Expanded, Scopus)

51. Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.

Zengin G., Ozyurt N., Beypinar I., Cinkir H. Y., Bilgin B., Gumusay Ö.

JOURNAL OF CLINICAL ONCOLOGY , sa.15, 2018 (SCI-Expanded, Scopus)

52. Kemiğin dev hücreli tümörü taklit eden primer hiperparatiroidizme bağlı brown tümörü

DEMİR A. K., KUTLUTÜRK F., GÜL S. S., GÜMÜŞAY Ö.

Journal of Contemporary Medicine , 2018 (TRDizin)

53. Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model

Cetin B., Yilmaz G. E., Armagan B., AFŞAR B., Demirci U., GÜLBAHAR Ö., et al.

CHEMOTHERAPY , cilt.63, sa.1, ss.39-45, 2018 (SCI-Expanded, Scopus)

54. Kolorektal Kanserlerde Güncel Tedavi Yaklaşımı

GÜLER AVCI G., GÜMÜŞAY Ö.

Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi , cilt.10, sa.1, ss.1-7, 2018 (Hakemli Dergi)

55. Kanserde Tarama ve Erken Tanı

GÜMÜŞAY Ö., GÜLER AVCI G.

Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi , cilt.9, sa.4, ss.210-221, 2017 (Hakemli Dergi)

56. The assessment of incidental thyroid lesions on 18F-fluorodeoxyglucose positron emission tomography/computed tomogrophy: A single centre experience

ALGIN E., ÜNER A., AKDEMİR Ü. Ö., GÜMÜŞAY Ö., KAPUCU Ö., ÖZET A.

Journal of Oncological Sciences , cilt.3, sa.2, ss.57-61, 2017 (Hakemli Dergi)

57. Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: a multicenter study of Anatolian Society of Medical Oncology.

Seber S., Turkmen E., Harputoğlu H., Yeşil H., Arpacι E., Menekşe S., et al.

European journal of gynaecological oncology , cilt.38, sa.2, ss.227-231, 2017 (SCI-Expanded, Scopus)

58. Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer

AYDİL U., AKMANSU M., Gumusay Ö., Bakkal F. K., Yazici O., KIZIL Y., et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.273, sa.9, ss.2795-2803, 2016 (SCI-Expanded, Scopus)

59. Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment

ALGIN E., GÜMÜŞAY Ö., DOĞAN M., ÖZET A.

Journal of Oncological Sciences , cilt.2, sa.2-3, ss.95-96, 2016 (TRDizin)

60. Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients

Gumusay Ö., Cetin B., Benekli M., Gurcan G., İLHAN M. N., Bostankolu B., et al.

JOURNAL OF CANCER EDUCATION , cilt.31, sa.2, ss.308-313, 2016 (SCI-Expanded, Scopus)

61. Advances of Molecular Targeted Therapy in Gastric Cancer

Cetin B., Gumusay Ö., Cengiz M., ÖZET A.

Journal of Gastrointestinal Cancer , cilt.47, sa.2, ss.125-134, 2016 (Scopus)

62. Crizotinib-induced toxicity in an experimental rat model

Gumusay Ö., Esendagli-Yilmaz G., ÜNER A., Cetin B., Buyukberber S., Benekli M., et al.

WIENER KLINISCHE WOCHENSCHRIFT , cilt.128, sa.11-12, ss.435-441, 2016 (SCI-Expanded, Scopus)

63. Tumor homing to the oral cavity after tooth extraction in a patient with metastatic lung adenocancer: A case report

GÜMÜŞAY Ö., BOSTANKOLU B., IŞIK GÖNÜL İ., ÖZET A.

Journal of Oncological Science , cilt.1, ss.5-7, 2016 (TRDizin)

64. Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients

Algin E., ÖZET A., Gumusay Ö., Yilmaz G., Buyukberber S., COŞKUN U., et al.

WIENER KLINISCHE WOCHENSCHRIFT , cilt.128, sa.1-2, ss.42-47, 2016 (SCI-Expanded, Scopus)

65. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors

Cetin B., Gonu I. I., Buyukberber S., Afsar B., Gumusay Ö., Algm E., et al.

TUMOR BIOLOGY , cilt.36, sa.11, ss.8471-8478, 2015 (SCI-Expanded, Scopus)

66. EKSTRAKRANİAL SKALP METASTAZI İLE PREZENTE OLAN NADİR BİR HEPATOSELLÜLER KANSER OLGUSU

GÜMÜŞAY Ö., DEMİRTAŞ A., ARICI A., GÖKÇE E., YILMAZ E. E., DEMİR A. K., et al.

Journal of Contemporary Medicine , cilt.0, sa.0, 2015 (Hakemli Dergi)

67. HIV Negatif Olguda Skrotal Kaposi Sarkomu

GÜMÜŞAY Ö., ARSLAN ŞEN T., ALICI Ö., TAKCI Z., ARSLAN KABALAY G. İ., SUHEYLA K. U., et al.

Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi , cilt.7, sa.3, ss.241-245, 2015 (Hakemli Dergi)

68. Small cell neuroendocrine carcinoma of the posterior tongue

Gumusay Ö., Yilmaz G., AYDİL U., ÖZET A., Tufan G., ERDEM O. A., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.11, sa.3, ss.651-0, 2015 (SCI-Expanded, Scopus)

69. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

Gumusay Ö., Benekli M., EKİNCİ Ö., Baykara M., ÖZET A., COŞKUN U., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , cilt.45, sa.5, ss.416-421, 2015 (SCI-Expanded, Scopus)

70. Factors predicting the development of distant metastases in patients with head and neck squamous cell carcinoma: A retrospective study from a single centre.

Gumusay Ö., Ozet A., Buyukberber S., Baykara M., Coskun U., Cetin B., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, sa.2, ss.521-6, 2015 (SCI-Expanded, Scopus)

71. Akciğerin Primer Şeffaf Hücreli Şeker Tümörü: Bir Olgu Sunumu

ALGIN E., GÜMÜŞAY Ö., IŞIK GÖNÜL İ., AKDEMİR Ü. Ö., ÖZET A.

Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi 20157(4):328-334 , cilt.7, sa.4, ss.328-334, 2015 (Hakemli Dergi)

72. Salvage chemotherapy with weekly paclitaxel for metastatic melanoma

Ozaslan E., Aksoy A., Gumusay Ö., Arpaci E., Berk V.

Asian Pacific Journal of Cancer Prevention , cilt.16, sa.6, ss.2581, 2015 (Scopus)

73. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin

Algin E., ÖZET A., Gumusay Ö., Cetin B., AKDEMİR Ü. Ö., Benekli M., et al.

ANNALS OF NUCLEAR MEDICINE , cilt.28, sa.9, ss.891-896, 2014 (SCI-Expanded, Scopus)

74. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay Ö., Yildiz R., et al.

BREAST CANCER , cilt.21, sa.6, ss.677-683, 2014 (SCI-Expanded, Scopus)

75. Factors predicting recurrence in patients with grade III glial tumors: impact of adjuvant temozolomide on recurrence.

Gumusay Ö., Cetin B., Ozet A., Demirci U., Buyukberber S., Coskun U., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.19, sa.4, ss.1035-40, 2014 (SCI-Expanded, Scopus)

76. Renal Hücreli Kanser Nedeniyle Nefrektomi Yapılan Olguda 16 yıl Sonra Gelişen İzole Beyin Metastazı Solitary Cerebral Metastases from Renal Cell Carcinoma 16 years After Nephrectomy

GÜMÜŞAY Ö., BENEKLİ M., EFNAN A., ONUR E., ULUOĞLU Ö., ÖNER A. Y., et al.

Acta Oncologica Turcica , 2014 (Hakemli Dergi)

77. Kanserde monoklonal antikorlarla küre yakın mıyız

ÖZET A., GÜMÜŞAY Ö.

Tüba Günce , sa.47, ss.7-10, 2014 (Hakemsiz Dergi)

78. Second primary tumors in patients with head and neck cancer A retrospective study from a single centre

GÜMÜŞAY Ö., ÖZET A., BAYKARA M., ÇETİN B., COŞKUN U., BÜYÜKBERBER S., et al.

Türkiye Klinikleri (J Med Sci ) , cilt.34, sa.2, ss.262-266, 2014 (Scopus)

79. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology

Gumusay Ö., COŞKUN U., Akman T., Ekinci A. S., Kocar M., Erceleb O. B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.140, sa.1, ss.151-157, 2014 (SCI-Expanded, Scopus)

80. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma

Cetin B., AFŞAR B., DEĞER S. M., IŞIK GÖNÜL İ., Gumusay Ö., ÖZET A., et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY , cilt.46, sa.6, ss.1081-1087, 2014 (SCI-Expanded, Scopus)

81. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B

Gumusay Ö., Ozenirler S., ATAK YÜCEL A., Sonmez C., ÖZKAN S., Tuncel A. F., et al.

HEPATOLOGY RESEARCH , cilt.43, sa.3, ss.228-237, 2013 (SCI-Expanded, Scopus)

82. Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay Ö., Yildiz R., et al.

ONCOLOGY , cilt.83, sa.3, ss.141-150, 2012 (SCI-Expanded, Scopus)

83. Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology

Kucukoner M., Isikdogan A., Yaman S., Gumusay Ö., Unal O., Ulas A., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.8, ss.3973-3976, 2012 (SCI-Expanded, Scopus)

84. Serum levels of advanced oxidation protein products, malonyldialdehyde, and total radical trapping antioxidant parameter in patients with chronic hepatitis C

Ozenirler S., Erkan G., GÜLBAHAR Ö., Bostankolu Ö., Demirel O. O., Bilgihan A., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.22, sa.1, ss.47-53, 2011 (SCI-Expanded, Scopus, TRDizin)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 18

1. Endokrin Tedavi Kullanan Meme Kanserli Kadınlarda Yogaya İlişkin Beklenti ve Deneyimler: Nitel Bir Çalışma

Gür G., Ardıç A., Can G., Gümüşay Ö.

II. Uluslararası Onkoloji Hemşireliği Derneği Kongresi, İstanbul, Türkiye, 7 - 09 Mayıs 2026, ss.20-21, (Özet Bildiri)

2. Clinical outcome and characteristics of Turkish breast cancer patients during SARSCov-2 pandemic: Single center experience.

Isoklar A., Soyder A., Gumusay Ö., Basaran G.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)

3. Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).

Gumusay Ö., Majure M. C., Deal T., Renslo J. R., Wabl C. A., Melisko M. E., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, (Özet Bildiri)

4. A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).

Gumusay Ö., Renslo J. R., Wabl C. A., Chien A. J., Melisko M. E., Majure M. C., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, (Özet Bildiri)

5. Can Target Sign Detected by DWI Be Used as an Assisting MRI Marker in the Differential Diagnosis of Liver Metastases?

ALBAYRAK E., GÜMÜŞAY Ö.

XVI. Balkan Congress of Radiology, 4 - 06 Ekim 2018, (Özet Bildiri)

6. Associations of Between IL-6 Gene Variation and Oral Squamous Cell Carcinoma (OSCC)

NURSAL A. F., YİĞİT S., TEKCAN A., GÜMÜŞAY Ö.

WITAM-2018: International Congress on the World of Technology and Advanced Materials, Kırşehir, Türkiye, 21 - 23 Eylül 2018, (Tam Metin Bildiri)

7. Oral Kanserli Hastalarda İnterleukin 6 Geni (IL6) Polimorfizmleri

YİĞİT S., NURSAL A. F., GÜMÜŞAY Ö., KARAKUŞ N., yılmaz K., Öz T.

International Eurasian Conference on Biological and Chemical Sciences, 26 - 27 Nisan 2018, (Özet Bildiri)

8. Oral kanserli hastalarda Interlökin- 6 (IL-6) gen polimorfizmleri

YİĞİT S., NURSAL A. F., GÜMÜŞAY Ö., KARAKUŞ N., Yılmaz E., Öz T.

INTERNATIONAL EURASIAN CONFERENCE ONBIOLOGICAL AND CHEMICAL SCIENCES, 26 - 27 Nisan 2018, (Özet Bildiri)

9. Oral kanserli hastalarda Interlökin-4 VNTR polimorfizmi

GÜMÜŞAY Ö., NURSAL A. F., YİĞİT S., TEKCAN A., Yılmaz K., KISMALI G.

INTERNATIONAL EURASIAN CONFERENCE ONBIOLOGICAL AND CHEMICAL SCIENCES, 26 - 27 Nisan 2018, (Özet Bildiri)

10. TÜRKIYE’DE METASTATIK MEME KANSERINDE HER2 HEDEFLITEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLILIKVERILERI

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., et al.

7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Türkiye, 21 - 24 Mart 2018, (Özet Bildiri)

11. The assessment of incidental thyroid lesions on 18F Flourodeoxyglucose positron emission tomography computed tomography A single centre experience

EFNAN A., BENEKLİ M., AKDEMİR Ü. Ö., GÜMÜŞAY Ö., COŞKUN U., YILDIZ R., et al.

ECCO-ESMO-ESTRO 2015, 25 - 29 Eylül 2015

15. The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival

ÇETİN B. E., TAŞTEKİN D., Aktas B., Guler T., Kaplan M. A., Berk V., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, (Özet Bildiri)

16. Clinical significance of Ezrin and Neuropilin-2 expression in advanced renal cell carcinoma

ÇETİN B. E., IŞIK GÖNÜL İ., Buyukberber S., Afsar B., Gumusay Ö., Benekli M., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, (Özet Bildiri)

17. Predictive factors for the development of brain metastases in patients with malignant melanoma: A study by the Anatolian Society of Medical Oncology

Gumusay Ö., Akman T., Ekinci A. S., Kocar M., Erceleb O. B., Kaplan M. A., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, (Özet Bildiri)

18. Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study

Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay Ö., Yildiz R., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, (Özet Bildiri)

Kitaplar 1

1. Kanser Tedavisinin Prensipleri

GÜMÜŞAY Ö.

Cecil Essentials of Medicine, Doç. Dr. Meltem Baykara, Editör, Güneş Kitapevi, Ankara, ss.585-591, 2016

Diğer Yayınlar 2

1. Abstract P4-11-03: Prediciting high risk hormone receptor (HR) positive Her-2 negative early breast cancer (BC) by artificial intelligence (AI) algorithms

Gümüşay Ö.

Sunum, ss.3-4, 2025

2. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Gümüşay Ö.

Diğer, ss.255-262, 2025

Yayınlar & Eserler